---
layout: default
title: Palbociclib
parent: 僅模型預測 (L5)
nav_order: 279
evidence_level: L5
indication_count: 4
---

# Palbociclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palbociclib: From Breast Cancer to Hyperthyroidism

## One-Sentence Summary

Palbociclib is a CDK4/6 inhibitor, per the literature captured in this evidence pack primarily developed for hormone receptor-positive, HER2-negative metastatic breast cancer. The TxGNN model's top-ranked prediction for this drug is **Hyperthyroidism**, but currently **zero clinical trials and zero publications** support this specific pairing — it is a computational prediction only.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Breast cancer (HR+/HER2-) — inferred from literature context in this pack; not confirmed via Taiwan/TFDA licensing data (none available) |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on literature context embedded in this pack, palbociclib is a CDK4/6 (cyclin-dependent kinase 4/6) inhibitor that blocks cell-cycle progression from G1 to S phase, and is established in HR+/HER2- metastatic breast cancer.

There is no known pathophysiological relationship between CDK4/6-mediated cell-cycle arrest and hyperthyroidism (a disorder of excess thyroid hormone secretion driven by thyroid gland/pituitary-axis dysregulation, not cell-cycle control). The repurposing rationale supplied with this candidate explicitly states there is no mechanistic link identified.

No clinical trials, published literature, or preclinical studies were found connecting palbociclib to hyperthyroidism (see query_log entries 5–7, all zero results). This prediction should be treated as an untested network-level hypothesis from TxGNN, not as a mechanistically or clinically supported signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Information

Palbociclib currently holds **0 marketing authorizations** in Taiwan (market status: 未上市 / not marketed). No license records are available in this evidence pack, and TFDA package insert data is flagged as a Blocking data gap (DG001).

---

## Cytotoxicity

Palbociclib is an oncology agent (CDK4/6 inhibitor class, established in breast cancer per the literature in this pack), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | High — literature within this evidence pack documents palbociclib-induced myelosuppression (neutropenia/thrombocytopenia) as a recognized class effect (PMID [39940918](https://pubmed.ncbi.nlm.nih.gov/39940918/), PMID [37994878](https://pubmed.ncbi.nlm.nih.gov/37994878/)) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential (neutrophil count); liver function; monitor for interstitial lung disease symptoms per PMID [37994878](https://pubmed.ncbi.nlm.nih.gov/37994878/) |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information (key warnings, contraindications, and DDI data are all unavailable — flagged as a Blocking data gap, DG001).

**Supplementary note (from literature, not formal safety data):** other candidate indications in this same evidence pack surfaced pharmacovigilance signals worth tracking independently — myelosuppression (PMID 39940918, 37994878) and thromboembolic events (PMID 35300061, 36794339, 39123221) associated with CDK4/6 inhibitors as a class.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN similarity score, there is no clinical trial, literature, or mechanistic evidence linking palbociclib to hyperthyroidism — evidence level is L5 (model prediction only), which does not meet the threshold to advance this specific candidate.

**To proceed, the following is needed:**
- TFDA package insert (warnings/contraindications) — currently Blocking data gap
- DrugBank-confirmed mechanism of action (MOA) — currently High-severity data gap
- Any preclinical/translational data establishing a plausible link between CDK4/6 inhibition and thyroid hormone regulation before further evaluation is warranted

**Note:** this evidence pack also includes a second candidate, **rheumatoid arthritis** (rank 2, score 99.36%), with substantially stronger support — a human case report of RA remission during palbociclib treatment, a 2025 review on CDK4/6 inhibitors and immune-mediated disease, and two preclinical studies on CDK6-driven synovial hyperplasia (Evidence Level L4, "Research Question" recommendation). If exploring repurposing directions for this drug, that candidate merits a separate, dedicated evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

